© 2024 Cogora - All Rights Reserved
'); slot2 = googletag.defineSlot('/21804779673/hpe_live/mpu1', [[300, 600], [300, 250], [300, 1000]], 'div-gpt-ad-1560526566997-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); slot3 = googletag.defineSlot('/21804779673/hpe_live/mpu2', [300,250], 'div-gpt-ad-1560784220575-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); slot4 = googletag.defineSlot('/21804779673/hpe_live/mpu3', [300,250], 'div-gpt-ad-1560784251022-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); slot5 = googletag.defineSlot('/21804779673/hpe_live/mpu4', [300, 250], 'div-gpt-ad-1563274753432-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/slider', [1, 1], 'div-gpt-slider').addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/skinleft', [146, 900], 'div-gpt-ad-1679485212314-0').addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/skinright', [146, 900], 'div-gpt-ad-1679485314324-0').addService(googletag.pubads()); slot1 = googletag.defineSlot('/21804779673/hpe_live/leaderboard', [[970, 250], [728, 90]], 'div-gpt-ad-1579859448100-0').setTargeting('test', 'event').setTargeting(REFRESH_KEY, REFRESH_VALUE).addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/footer', [728, 90], 'div-gpt-ad-1563274691467-0').addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/Overlay', [640, 480], 'div-gpt-ad-1642681358066-0').addService(googletag.pubads()); googletag.defineSlot('/21804779673/hpe_live/stickyfoot', [ [970, 250], [728, 90] ], 'dfp_stickyfooter').addService(googletag.pubads()); var targeturl="degarelix"; console.log("DFP set url-hpe='"+targeturl+"'"); googletag.pubads().collapseEmptyDivs(); googletag.pubads().enableSingleRequest(); // googletag.pubads().disableInitialLoad(); // BDG 03.03.2021 googletag.pubads().enableLazyLoad({ fetchMarginPercent: 0, // When the slot enters the viewport. renderMarginPercent: 0, }); googletag.enableServices(); }); //--> jQuery(window).scroll(function() { checkStick(); }); var mbannerid = '#div-gpt-ad-1563273235586-0'; var mfooterid = '#footermobilebanner'; var dfooterid = '#div-gpt-ad-1563274691467-0'; // Desktop sticky check function checkStick() { var launched = false; if (jQuery(window).height() > 500) { if (!jQuery('#dfp_stickyfooter').hasClass("closed")) { if (jQuery('#dfp_stickyfooter > div').length) { if (!jQuery('#dfp_stickyfooter > div').hasClass("cog-mb-sticky")) { var width = jQuery('#dfp_stickyfooter > div > iframe').width(); var height = jQuery('#dfp_stickyfooter > div > iframe').height(); if (parseInt(width) > 0) { launched = true; jQuery('#dfp_stickyfooter').attr('style', 'height: '+(height+30)+'px;').addClass('opened'); jQuery('#dfp_stickyfooter').append(' '); jQuery('#dfp_stickyfooter > div').addClass('cog-mb-sticky floating footer'); jQuery('#dfp_stickyfooter > div').attr('style', 'position:absolute; bottom:0;'); jQuery('#dfp_stickyfooter svg.close').on('click', function() { jQuery(this).parent().removeClass('opened').addClass('closed'); }); } } } } } if (!launched) { // Ad not ready yet window.setTimeout(checkStick, 250); } } jQuery(document).ready(function() {checkStick();});

This site is intended for health professionals only

Degarelix

Cilta-cel approved by EC as second-line R/R multiple myeloma treatment
23 April 2024
Cilta-cel approved by EC as second-line R/R multiple myeloma treatment
by Helena Beer
New tool for calculating carbon footprint of medicines launched
23 April 2024
New tool for calculating carbon footprint of medicines launched
by Helena Beer
Fourth indication for bimekizumab as EC approves drug for hidradenitis suppurativa
23 April 2024
Fourth indication for bimekizumab as EC approves drug for hidradenitis suppurativa
by Helena Beer
Semaglutide beneficial in patients with type 2 diabetes and obesity-related heart failure
23 April 2024
Semaglutide beneficial in patients with type 2 diabetes and obesity-related heart failure
by Helena Beer
Some progestogen medicines associated with increased risk of meningioma, say researchers
15 April 2024
Some progestogen medicines associated with increased risk of meningioma, say researchers
by Helena Beer
No evidence of causal link between GLP-1 receptor agonists and suicide, says PRAC
15 April 2024
No evidence of causal link between GLP-1 receptor agonists and suicide, says PRAC
by Helena Beer
Lixisenatide shows potential in slowing Parkinsons disease progression
15 April 2024
Lixisenatide shows potential in slowing Parkinson’s disease progression
by Helena Beer
Tisagenlecleucel recommended for routine NHS rollout to treat R/R B-cell ALL
12 April 2024
Tisagenlecleucel recommended for routine NHS rollout to treat R/R B-cell ALL
by Helena Beer
Atogepant recommended by NICE as first oral drug for chronic and episodic migraine prophylaxis
12 April 2024
Atogepant recommended by NICE as first oral drug for chronic and episodic migraine prophylaxis
by Helena Beer
9 of 1


Most read

1
Transcranial magnetic stimulation brain connectivity changes in major depression visible on MRI scan
2
Oral vitamin A could become an alternative to isotretinoin for acne
3
Amino acids supplement reduces muscle wasting and improves gut function in critically ill
4
Less than two-thirds of patients alive 10 years after out-of-hospital cardiac arrest
5
Launch of the new Hospital Pharmacy Europe Mobile App



Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Subscribe

Download Hospital Pharmacy Europe free app

Download our app from the Apple App Store Download our app from Google Play

© Cogora 2024
Cogora Limited. 1 Giltspur Street, London EC1A 9DD Registered in the United Kingdom. Reg. No. 2147432

Cogora
x